NanoSphere Products Approved for Sale in California Cannabis Market

Vancouver (April 2, 2019)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) is pleased to announce its Evolve cannabis products will be available for purchase in California for the first time, after receiving final approval by the State of California.

NanoSphere’s Evolve Formula NanoSerum™is expected to hit store shelves in the Los Angeles area by April 8th.

NanoSerum™ is a transdermal serum that immediately penetrates the skin to deliver direct-focused relief from pain, inflammation, and anxiety. The serum is able to easily pass through the skin due to NanoSphere’s patented nanoparticle technology.

The Evolve Formulas serum will begin shipping to retail outlets next week, said NanoSphere President David Sutton. “This is another major step for our Evolve Formulas line of cannabis products, as we are now moving into the largest legal cannabis market in the world,” Sutton said.

“We have had a great response to our NanoSerumTM in Colorado, and now this revolutionary product will be available to the people of California for the first time.”

The NanoSerum is produced and distributed in California by Vertical, one of the first and largest vertically integrated companies in the legal US medical cannabis industry. (vertcos.com) Vertical operates cannabis growing and extract operations, but also features world-class capabilities in product development, co- packing, branding, marketing, distribution and legal compliance.

“Vertical has been a great partner for our expansion into the California market,” said NanoSphere CEO Robert Sutton. “They have deep experience in marketing, distribution and regulatory from their past experience in the alcohol industry, and the same commitment to excellence has been applied to the cannabis industry.”

Vertical President J. Smoke Wallin said the approval of NanoSphere’s technology marks a new turning point in the cannabis industry. “Our team is dedicated to building out the industry’s leading sales and distribution platform in multiple markets, and a big part of that is bringing our customers the most advanced products for both the medical and recreational markets,” Wallin said. “We couldn’t be more excited to bring NanoSphere’s cutting edge solution Evolve to our licensed retailers and medical dispensaries in California.”

NanoSphere is preparing a second line of products to register for sale in the California and Colorado recreational cannabis markets. The Evolve Formulas NanoGelTM is produced by encapsulating a full spectrum of cannabinoids and terpenes in smart lipid nanoparticles, which are transported through the mucous membrane and into the bloodstream, activating target receptors in the brain within minutes.

Evolve Formulas NanoGelTM provides a faster onset, precise dosing, higher bioavailability, and a similar effect to smoking or vaping cannabis, but without the potential harm to the lungs.

Analysis by Cowen & Co. predicts the cannabis industry in the United States is expected to grow to $50 billion by 2026, with California accounting for about $25 billion of that market, according to a report by Cannabis Financial Network (CFN: https://www.prnewswire.com/news-releases/california-cannabis- market-expected-to-reach-51-billion-market-value-685917412.html)

On behalf of the Board

David Sutton, President and COO
720.845.1466
dsutton@nanospherehealth.com

Media Contact:

Gary Symons
Mobile: 250.300.9352
E-mail: gsymons@nanospherehealth.com

About NanoSphere

NanoSphere Health Sciences LLC, is a biotechnology firm specializing in the creation of the NanoSphere Delivery SystemTM, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on NanoSphere, please visit http://www.nanospherehealth.com.

About Evolve FormulasTM

Evolve Formulas is the provider of the world's first and only scientifically proven nanoparticle delivery system in cannabis. Evolve’s pioneering product, Transdermal NanoSerumTM, is a fast- acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. For more information on Evolve Formulas, visit https:// www.evolveformulas.com/. Follow us on Facebook, Instagram and Twitter.

About VerticalTM

Vertical is a leading vertically-integrated multi-state operator and brand and distribution company in the medical and adult-use cannabis and Hemp-based CBD industries. With have operations in AZ, KY, and CA, combined with strategic partnerships in OH and additional markets which position it well to take advantage of the legalization and normalization of cannabis globally. Vertical is led by an executive team of entrepreneurs and business leaders from the alcohol beverage, agriculture, CPG, distribution, entertainment, food, healthcare, and medical industries.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statement Caution

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's

intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Without limitation, these include assumptions, risks and uncertainties inherent in completing sub-licensing arrangements in the United States, Canada and abroad, product demand, production, competition and government regulation of the Cannabis industry, any and all of which may have an adverse effect on the Company’s expansion plans, sales, revenues and its financial results and condition. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.

Samuel TheilComment